Lumitin (conbercept) / Chengdu Kanghong Pharma 
Welcome,         Profile    Billing    Logout  
 27 Diseases   27 Trials   27 Trials   307 News 


12345678»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
    Retrospective data, Review, Journal:  Comparative efficacy and safety of anti-VEGF agents with and without Laser therapy for diabetic macular edema: A network meta-analysis. (Pubmed Central) -  Jul 1, 2025   
    For Best-Corrected Visual Acuity (BCVA), both Ranibizumab and Ranibizumab?+?laser achieved statistically significant gains at 6 and 12 months compared to laser alone, with Ranibizumab?+?laser consistently ranking highest in efficacy. Safety analysis revealed no significant differences in total adverse event rates across treatments.ConclusionRanibizumab?+?laser therapy demonstrated the greatest improvement in CRT and BCVA at 3, 6, and 12 months, with no significant differences in adverse events compared to other anti-VEGF options.
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Lumitin (conbercept) / Chengdu Kanghong Pharma
    Clinical, Journal:  Early combined conbercept and dexamethasone implant therapy for diabetic macular edema. (Pubmed Central) -  Jun 27, 2025   
    Safety analysis revealed no significant differences in total adverse event rates across treatments.ConclusionRanibizumab?+?laser therapy demonstrated the greatest improvement in CRT and BCVA at 3, 6, and 12 months, with no significant differences in adverse events compared to other anti-VEGF options. Early combined therapy with dexamethasone implant (Ozurdex) and Conbercept injections offers significant clinical benefits for the treatment of DME during the initial three months of treatment.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Biomarker, Journal:  Prognostic factors of conbercept intravitreal injection in the treatment of choroidal neovascularization secondary to pathologic myopia. (Pubmed Central) -  Jun 18, 2025   
    The factors BCVA after treatment were analyzed using logistic regression analysis.ResultsTwelve months after treatment, there were 77 patients in the improved group and 23 in the non-improved group. Multivariable logistic regression analysis revealed that age (odds ratio (OR)?=?1.303, 95% confidence interval (CI): 1.059-1.603, P?=?0.012), baseline BCVA (OR?=?15.939, 95% CI: 2.490-102.013, P?=?0.003), subfoveal CNV (OR?=?0.055, 95% CI: 0.010-0.312, P?=?0.001), and well-organized CNV (OR?=?0.049, 95% CI: 0.009-0.276, P?=?0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Enrollment closed:  Efficacy and Safety of Conbercept for Diabetic Macular Edema Combined With Severe Non-proliferative Diabetic Retinopathy (clinicaltrials.gov) -  May 30, 2025   
    P4,  N=58, Active, not recruiting, 
    Multivariable logistic regression analysis revealed that age (odds ratio (OR)?=?1.303, 95% confidence interval (CI): 1.059-1.603, P?=?0.012), baseline BCVA (OR?=?15.939, 95% CI: 2.490-102.013, P?=?0.003), subfoveal CNV (OR?=?0.055, 95% CI: 0.010-0.312, P?=?0.001), and well-organized CNV (OR?=?0.049, 95% CI: 0.009-0.276, P?=?0.001) were independently associated with the efficacy of intravitreal injection of conbercept in patients with PM-CNV.ConclusionPoor postoperative BCVA recovery in patients with PM-CNV after conbercept intravitreal injection could be associated with age, baseline BCVA, and location and morphology of CNV. Recruiting --> Active, not recruiting
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Anti-Vascular Endothelial Growth Factor Crunch Syndrome in Proliferative Diabetic Retinopathy. (Pubmed Central) -  Apr 21, 2025   
    A 33-year-old male individual with proliferative diabetic retinopathy (PDR) received a single intravitreal injection of conbercept (Kanghong Inc., Chengdu, China) for vitreous hemorrhage in his right eye...However, at the 3-month follow-up, visual acuity remained limited to counting fingers. This case highlights crunch syndrome as a rare but serious complication of intravitreal anti-VEGF therapy for PDR, emphasizing the need for careful patient selection and close postoperative monitoring.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Re: Cheng et (Pubmed Central) -  Apr 10, 2025   
    This case highlights crunch syndrome as a rare but serious complication of intravitreal anti-VEGF therapy for PDR, emphasizing the need for careful patient selection and close postoperative monitoring. No abstract available
  • ||||||||||  Economic Modelling of Myopia Management: A Systematic Literature Review () -  Mar 24, 2025 - Abstract #ISPOR2025ISPOR_2032;    
    This SLR highlighted the diverse economic modelling approaches used to assess myopia management strategies, predominantly evaluated in Asian populations. With the increasing prevalence of myopia, its geographic spread and long-term clinical manifestations, there is a need for more comprehensive framework for economic evaluations in myopia.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  INTRAVITREAL INJECTION CONBERCEPT IMPROVES THE BEST-CORRECTED VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR EDEMA. (Pubmed Central) -  Oct 23, 2024   
    Furthermore, microvascular irregularities were correlated with central foveal thickness. The BCVA values of the effective group were lower than those of the ineffective group, and the BCVA changes of the effective group before and after treatment were greater than those of the ineffective group, suggesting that conbercept can improve the visual acuity of patients with macular edema caused by wet age-related macular degeneration.
  • ||||||||||  Clinical, Retrospective data:  Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis. (Pubmed Central) -  Jul 30, 2024   
    The aim of this study was to compare the efficacy of intravitreal aflibercept (IVA), intravitreal bevacizumab (IVB), intravitreal conbercept (IVC), intravitreal ranibizumab (IVR), and laser therapy in treating these conditions...Our analysis concludes that intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) drug monotherapy generally offer better outcomes than laser treatment for ROP. Nonetheless, additional RCTs are necessary to further evaluate the safety of anti-VEGF agents.
  • ||||||||||  Lumitin (conbercept) / Chengdu Kanghong Pharma
    Retrospective data, Journal:  Clinical and genetic features in autosomal recessive bestrophinopathy in Chinese cohort. (Pubmed Central) -  Jul 26, 2024   
    This study provides a comprehensive characterization of anterior segment and genetic features in ARB, with a wide array of morphological abnormalities. Findings are relevant for refining clinical practices and genetic counseling and advancing pathogenesis research.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lumitin (conbercept) / Chengdu Kanghong Pharma
    Clinical, Journal:  Comparative study on the efficacy of Conbercept and Aflibercept in the treatment of neovascular age-related macular degeneration. (Pubmed Central) -  May 26, 2024   
    P2/3
    Both Conbercept and Aflibercept are clinically similar in efficacy for nAMD, with the T&E regimen proving therapeutically effective and potentially reducing patient costs. Anti-VEGF treatment efficacy varies across nAMD subtypes, indicating a potential benefit in tailored treatments for specific subtypes.Clinical trial registration number NCT05539235 (Protocol Registration and Results System).
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie
    Clinical:  The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy. (Pubmed Central) -  Mar 13, 2024   
    Ozurdex may help to improve the visual acuity and visual sensitivity, and there is no significant difference in the change of IOP and microvascular improvement. This trial is registered with the Chinese Clinical Trial Registry (http://www.chictr.org.cn, registration number ChiCTR2100043399).
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis, Lumitin (conbercept) / Chengdu Kanghong Pharma
    Journal:  Clinical evaluation of ranibizumab and conbercept for the treatment of macular oedema secondary to central retinal vein occlusion. (Pubmed Central) -  Mar 6, 2024   
    This NMA showed intravitreal faricimab regimens resulted in statistically beneficial effects on BCVA improvement and CMT reduction, also had the highest probability of being the most effective options in VFQ-25 scores, number of injections and a higher proportion of patients with a gain of at least 15 ETDRS letters compared to ranibizumab, conbercept, aflibercept or laser group after one-year treatment in China. No abstract available